Risk reduction of non-vertebral fractures with intravenous ibandronate: Post-hoc analysis from DIVA

Current Medical Research and Opinion

Volumn 26, Issue 3, 2010, Pages 599-604

  Sambrook, Philip ^a   Cranney, Ann ^b   Adachi, Jonathan D ^c  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Bisphosphonates; Bone fractures; Ibandronate; Intravenous; Postmenopausal osteoporosis

Indexed keywords

CALCIUM; COLLAGEN TYPE 1; IBANDRONIC ACID; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITOMETRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; FRACTURE; HAZARD RATIO; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FRACTURES, BONE; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; MIDDLE AGED;

EID: 76949107500     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903512321     Document Type: Article

References (35)

1. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-1541
2. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280: 2077-2082
3. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-1352
4. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91
5. Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-1249
6. Boonen S, Vanderschueren D, Venken K, et al. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance. J Intern Med 2008;264:315-332
7. Lewiecki EM, Babbitt AM, Piziak VK, et al. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation. Clin Ther 2008;30:605-621
8. Silverman SL, Gold DT. Compliance and persistence with osteoporosis therapies. Curr Rheumatol Rep 2008;10:118-122
9. Cauley JA, Thompson DE, Ensrud KC, et al. Risk of mortality following clinical fractures. Osteoporos Int 2000;11:556-561
10. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005;16(Suppl 2):S3-7
11. Caliri A, De Filippis L, Bagnato GL, et al. Osteoporotic fractures: mortality and quality of life. Panminerva Med 2007;49:21-27
12. Johnell O, Kanis JA, Oden A, et al. Mortality after osteoporotic fractures. Osteoporos Int 2004;15:38-42
13. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-1733
14. Iacovino JR. Mortality outcomes after osteoporotic fractures in men and women. J Insur Med 2001;33:316-320
15. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007;22:465-475
16. Keen RW. Burden of osteoporosis and fractures. Curr Osteoporos Rep 2003; 1:66-70
17. Johnell O, Kanis JA, Jonsson B, et al. The burden of hospitalised fractures in Sweden. Osteoporos Int 2005;16:222-228
18. Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal osteoporosis: 1-year findings from the DIVA study. Arthritis Rheum 2006;54:1838-1846
19. Eisman J, Civitelli R, Adami S, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 2008;35:488-497
20. Papapoulos S. Changes in bone remodeling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with iban-dronate. Ann Rheum Dis 2007;66:853-858
21. Cranney A, Wells GA, Yetisir E, et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporosis Int 2008;20:291-297
22. Barrett J, Worth E, Bauss F, et al. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 2004;44:951-965
23. Cremers SC, Pillai G, Papapoulos SE. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimization of intermittent therapy for osteoporosis. Clin Pharmacokinet 2005;44:551-570
24. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005;20:1315-1322
25. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:654-661
26. Schneider DL, Bettencourt R, Barrett-Connor E. Clinical utility of spine bone density in elderly women. J Clin Densitom 2006; 9:255-260
27. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-1767
28. Durosier C, Hans D, Krieg MA, et al. Prediction and discrimination of osteoporotic hip fracture in postmenopausal women. J Clin Densitom 2006;9:475-495
29. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005;20:1185-1194
30. Kanis JA, Odén A, Johnell O, et al. The components of excess mortality after hip fracture. Bone 2003;32:468-473
31. Sernbo I, Johnell O. Consequences of a hip fracture: a prospective study over 1 year. Osteoporos Int 1993;3:148-153
32. Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 2008;24:237-245
33. Hadji P, Minne H, Pfeifer M, et al. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). Joint Bone Spine 2008;75:303-310
34. Cooper A, Drake J, Brankin E; the PERSIST Investigators. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006;60: 896-905
35. Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva ALendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895-1903